Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
ITRM
ITRM
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ITRM News
ITERUM THERAPEUTICS PLC: FDA Suggests Type C Meeting for Proposed Clinical Study of ORLYNVAH
3d ago
moomoo
IO Biotech (IOBT) Explores Strategic Alternatives, Stock Surges 19.36%
Jan 22 2026
NASDAQ.COM
Iterum Expands ORLYNVAH™ Coverage to 25 Million Lives in the U.S.
Dec 05 2025
Globenewswire
Butterfly Network and Citius Pharma Boost Biotech Activity in After-Hours Trading
Nov 24 2025
NASDAQ.COM
Applied Therapeutics, Omeros, and Others Experience Significant Price Changes After Market Close
Nov 14 2025
NASDAQ.COM
Earnings Report Ahead of Market Opening for November 14, 2025: SR, SRRK, TWST, BTBT, SGML, FRGE, SBC, GAUZ, INKT, MRSN, ITRM, LMFA
Nov 13 2025
NASDAQ.COM
Key Stocks Reporting Earnings This Week: Plug, Oklo, Circle, and Others
Nov 10 2025
Benzinga
Iterum Therapeutics Projects Sufficient Cash Reserves Through 2026
Sep 20 2025
Yahoo Finance
Iterum Therapeutics Shares Latest Business Developments
Sep 19 2025
Newsfilter
Iterum Therapeutics Introduces ORLYNVAH™, the First and Only Oral Penem Antibiotic Available in the U.S.
Aug 20 2025
Newsfilter
ITRM Reports Results
Aug 06 2025
NASDAQ.COM
Iterum Names Christine Coyne as Chief Commercial Officer to Lead ORLYNVAH™ Launch and Commercial Growth
Jun 30 2025
Newsfilter
Iterum Therapeutics Announces Publication of REASSURE Trial in NEJM Evidence
Jun 25 2025
Newsfilter
Iterum Therapeutics Announces Partnership for Commercialization Services
Jun 11 2025
Newsfilter
Iterum Therapeutics Inks Partnership With EVERSANA For Commercialization Of ORLYNVAH In US
Jun 11 2025
NASDAQ.COM
Iterum Therapeutics Announces Extension of Term of Promissory Note
May 19 2025
Newsfilter
Show More News
